References
- S. Mondal, N. Adhikari, S. Banerjee, S.A. Amin, and T. Jha, Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview, Eur. J. Med. Chem. 194 (2020), pp. 112–260. doi:https://doi.org/10.1016/j.ejmech.2020.112260.
- V. Hugenberg and G. Haufe, Fluorinated matrix metalloproteinase inhibitors (MMPIs) for potential application in therapy and diagnosis of diseases, Front. Organofluorine Chem. (2020), pp. 447–516. doi:https://doi.org/10.1142/9781786347336_0009.
- S.K. Baidya, S.A. Amin, and T. Jha, Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present, Eur. J. Med. Chem. 213 (2021), pp. 113044. doi:https://doi.org/10.1016/j.ejmech.2020.113044.
- S. Mondal, S. Banerjee, S.A. Amin, and T. Jha, Structural analysis of arylsulfonamide-based carboxylic acid derivatives: A QSAR study to identify the structural contributors toward their MMP-9 inhibition, Struct. Chem. 32 (2021), pp. 417–430. doi:https://doi.org/10.1007/s11224-020-01635-4.
- A. Alaseem, K. Alhazzani, P. Dondapati, S. Alobid, A. Bishayee, and A. Rathinavelu, Matrix metalloproteinases: A challenging paradigm of cancer management, Semin. Cancer Biol. 56 (2019), pp. 100–115. doi:https://doi.org/10.1016/j.semcancer.2017.11.008.
- M. Egeblad and Z. Werb, New functions for the matrix metalloproteinases in cancer progression, Nat. Rev. Cancer 2 (2002), pp. 161–174. doi:https://doi.org/10.1038/nrc745.
- K. Juurikka, G.S. Butler, T. Salo, P. Nyberg, and P. Åström, The role of MMP8 in cancer: A systematic review, Int. J. Mol. Sci. 20 (2019), pp. 4506. doi:https://doi.org/10.3390/ijms20184506.
- A. Tokito and M. Jougasaki, Matrix metalloproteinases in non-neoplastic disorders, Int. J. Mol. Sci. 17 (2016), pp. 1178. doi:https://doi.org/10.3390/ijms17071178.
- P. Van Lint and C. Libert, Matrix metalloproteinase-8: Cleavage can be decisive, Cytokine Growth Factor Rev. 17 (2006), pp. 217–223. doi:https://doi.org/10.1016/j.cytogfr.2006.04.001.
- R. Visse and H. Nagase, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry, Circ. Res. 92 (2003), pp. 827–839. doi:https://doi.org/10.1161/01.RES.0000070112.80711.3D.
- K. Li, F.R. Tay, and C.K. Yiu, The past, present and future perspectives of matrix metalloproteinase inhibitors, Pharmacol. Ther. 207 (2020), pp. 107465. doi:https://doi.org/10.1016/j.pharmthera.2019.107465.
- C. Tallant, A. Marrero, and F.X. Gomis-Rüth, Matrix metalloproteinases: Fold and function of their catalytic domains, Biochim. Biophys Acta Mol. Cell. Res. 1803 (2010), pp. 20–28. doi:https://doi.org/10.1016/j.bbamcr.2009.04.003.
- K. Prikk, E. Pirilä, R. Sepper, P. Maisi, T. Salo, J. Wahlgren, and T. Sorsa, In vivo collagenase‐2 (MMP‐8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis, J. Pathol. 194 (2001), pp. 232–238. doi:https://doi.org/10.1002/path.849.
- A. Jabłońska-Trypuć, M. Matejczyk, and S. Rosochacki, Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs, J. Enzyme Inhib. Med. Chem. 31 (2016), pp. 177–183. doi:https://doi.org/10.3109/14756366.2016.1161620.
- P.D. Solan, K.E. Dunsmore, A.G. Denenberg, K. Odoms, B. Zingarelli, and H.R. Wong, A novel role for matrix metalloproteinase-8 in sepsis, Crit. Care Med. 40 (2012), pp. 379–387. doi:https://doi.org/10.1097/CCM.0b013e318232e404.
- D. Demeestere, E. Dejonckheere, S. Steeland, P. Hulpiau, J. Haustraete, N. Devoogdt, R. Wichert, C. Becker-Pauly, E. Van Wonterghem, S. Dewaele, and G. Van Imschoot, Development and validation of a small single-domain antibody that effectively inhibits matrix metalloproteinase 8, Mol. Ther. 24 (2016), pp. 890–902. doi:https://doi.org/10.1038/mt.2016.2.
- H. Kumar, M.J. Jo, H. Choi, M.S. Muttigi, S. Shon, B.J. Kim, S.H. Lee, and I.B. Han, Matrix metalloproteinase-8 inhibition prevents disruption of blood–spinal cord barrier and attenuates inflammation in rat model of spinal cord injury, Mol. Neurobiol. 55 (2018), pp. 2577–2590. doi:https://doi.org/10.1007/s12035-017-0509-3.
- A. Lauhio, E. Färkkilä, K.H. Pietiläinen, P. Åström, A. Winkelmann, T. Tervahartiala, E. Pirilä, A. Rissanen, J. Kaprio, T.A. Sorsa, and T. Salo, Association of MMP‐8 with obesity, smoking and insulin resistance, Eur. J. Clin. Invest. 46 (2016), pp. 757–765. doi:https://doi.org/10.1111/eci.12649.
- A.M. Tester, J.H. Cox, A.R. Connor, A.E. Starr, R.A. Dean, X.S. Puente, C. López-Otín, and C.M. Overall, LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity, PloS One 2 (2007), pp. e312. doi:https://doi.org/10.1371/journal.pone.0000312.
- S. García, J. Forteza, C. López-Otin, J.J. Gómez-Reino, A. González, and C. Conde, Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model, Arthritis Res. Ther. 12 (2010), pp. 1–12. doi:https://doi.org/10.1186/ar3211.
- J.E. Han, E.J. Lee, E. Moon, J.H. Ryu, J.W. Choi, and H.S. Kim, Matrix metalloproteinase-8 is a novel pathogenetic factor in focal cerebral ischemia, Mol. Neurobiol. 53 (2016), pp. 231–239. doi:https://doi.org/10.1007/s12035-014-8996-y.
- E.J. Lee, J.E. Han, M.S. Woo, J.A. Shin, E.M. Park, J.L. Kang, P.G. Moon, M.C. Baek, W.S. Son, Y.T. Ko, and J.W. Choi, Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-α activation, J. Immunol. 193 (2014), pp. 2384–2393. doi:https://doi.org/10.4049/jimmunol.1303240.
- C.W. Ong, P.T. Elkington, S. Brilha, C. Ugarte-Gil, M.T. Tome-Esteban, L.B. Tezera, P.J. Pabisiak, R.C. Moores, T. Sathyamoorthy, V. Patel, and R.H. Gilman, Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis, PLoS Pathog. 11 (2015), pp. e1004917. doi:https://doi.org/10.1371/journal.ppat.1004917.
- E.J. Lee, M.J. Choi, G. Lee, B.P. Gaire, J.W. Choi, and H.S. Kim, Regulation of neuroinflammation by matrix metalloproteinase-8 inhibitor derivatives in activated microglia and astrocytes, Oncotarget 8 (2017), pp. 78677–78690. doi:https://doi.org/10.18632/oncotarget.20207.
- J. Spiegel and H. Senderowitz, Evaluation of QSAR equations for virtual screening, Int. J. Mol. Sci. 21 (2020), pp. 7828. doi:https://doi.org/10.3390/ijms21217828.
- A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y.C. Martin, R. Todeschini, and V. Consonni, QSAR modeling: Where have you been? Where are you going to?, J. Med. Chem. 57 (2014), pp. 4977–5010. doi:https://doi.org/10.1021/jm4004285.
- E. Zvinavashe, A.J. Murk, and I.M. Rietjens, Promises and pitfalls of quantitative structure− Activity relationship approaches for predicting metabolism and toxicity, Chem. Res. Toxicol. 21 (2008), pp. 2229–2236. doi:https://doi.org/10.1021/tx800252e.
- P.P. Roy, S. Paul, I. Mitra, and K. Roy, On two novel parameters for validation of predictive QSAR models, Molecules 14 (2009), pp. 1660–1701. doi:https://doi.org/10.3390/molecules14051660.
- A. Topai, P. Breccia, F. Minissi, A. Padova, S. Marini, and I. Cerbara, In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors, Bioorg. Med. Chem. 20 (2012), pp. 2323–2337. doi:https://doi.org/10.1016/j.bmc.2012.02.010.
- J.Y. Choi, R. Fuerst, A.M. Knapinska, A.B. Taylor, L. Smith, X. Cao, P.J. Hart, G.B. Fields, and W.R. Roush, Structure-based design and synthesis of potent and selective matrix metalloproteinase 13 inhibitors, J. Med. Chem. 60 (2017), pp. 5816–5825. doi:https://doi.org/10.1021/acs.jmedchem.7b00514.
- H. Matter, W. Schwab, D. Barbier, G. Billen, B. Haase, B. Neises, M. Schudok, W. Thorwart, H. Schreuder, V. Brachvogel, and P. Lönze, Quantitative structure− activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis, J. Med. Chem. 42 (1999), pp. 1908–1920. doi:https://doi.org/10.1021/jm980631s.
- S.M. Marques, T. Tuccinardi, E. Nuti, S. Santamaria, V. André, A. Rossello, A. Martinelli, and M.A. Santos, Novel 1-hydroxypiperazine-2, 6-diones as new leads in the inhibition of metalloproteinases, J. Med. Chem. 54 (2011), pp. 8289–8298. doi:https://doi.org/10.1021/jm200593b.
- S.M. Marques, E. Nuti, A. Rossello, C.T. Supuran, T. Tuccinardi, A. Martinelli, and M.A. Santos, Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: Iminodiacetyl-based hydroxamate− benzenesulfonamide conjugates, J. Med. Chem. 51 (2008), pp. 7968–7979. doi:https://doi.org/10.1021/jm800964f.
- N. Adhikari, A.K. Halder, S. Mallick, A. Saha, K.D. Saha, and T. Jha, Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays, Bioorg. Med. Chem. 24 (2016), pp. 4291–4309. doi:https://doi.org/10.1016/j.bmc.2016.07.023.
- R.P. Verma and C. Hansch, Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q) SARs, Bioorg. Med. Chem. 15 (2007), pp. 2223–2268. doi:https://doi.org/10.1016/j.bmc.2007.01.011.
- S. Pikul, N.E. Ohler, G. Ciszewski, M.C. Laufersweiler, N.G. Almstead, B. De, M.G. Natchus, L.C. Hsieh, M.J. Janusz, S.X. Peng, and T.M. Branch, Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases, J. Med. Chem. 44 (2001), pp. 2499–2502. doi:https://doi.org/10.1021/jm015531s.
- H. Nara, K. Sato, A. Kaieda, H. Oki, H. Kuno, T. Santou, N. Kanzaki, J. Terauchi, O. Uchikawa, and M. Kori, Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors, Bioorg. Med. Chem. 24 (2016), pp. 6149–6165. doi:https://doi.org/10.1016/j.bmc.2016.09.009.
- R. Nakai, C.M. Salisbury, H. Rosen, and B.F. Cravatt, Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study, Bioorg. Med. Chem. 17 (2009), pp. 1101–1108. doi:https://doi.org/10.1016/j.bmc.2008.03.018.
- A. Rossello, E. Nuti, P. Carelli, E. Orlandini, M. Macchia, S. Nencetti, M. Zandomeneghi, F. Balzano, G.U. Barretta, A. Albini, and R. Benelli, N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP, Bioorg. Med. Chem. Lett. 15 (2005), pp. 1321–1326. doi:https://doi.org/10.1016/j.bmcl.2005.01.024.
- E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli, V.L. Pietra, E. Novellino, E. Orlandini, S. Nencetti, and T. Tuccinardi, N-O-isopropyl sulfonamido-based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis, J. Med. Chem. 52 (2009), pp. 4757–4773. doi:https://doi.org/10.1021/jm900261f.
- E. Nuti, L. Panelli, F. Casalini, S.I. Avramova, E. Orlandini, S. Santamaria, S. Nencetti, T. Tuccinardi, A. Martinelli, G. Cercignani, and N. D’Amelio, Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors, J. Med. Chem. 52 (2009), pp. 6347–6361. doi:https://doi.org/10.1021/jm900335a.
- A. Biasone, P. Tortorella, C. Campestre, M. Agamennone, S. Preziuso, M. Chiappini, E. Nuti, P. Carelli, A. Rossello, F. Mazza, and C. Gallina, alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs, Bioorg. Med. Chem. 15 (2007), pp. 791–799. doi:https://doi.org/10.1016/j.bmc.2006.10.047.
- D. Georgiadis and A. Yiotakis, Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge, Bioorg. Med. Chem. 16 (2008), pp. 8781–8794. doi:https://doi.org/10.1016/j.bmc.2008.08.058.
- J. Li, T.S. Rush III, W. Li, D. DeVincentis, X. Du, Y. Hu, J.R. Thomason, J.S. Xiang, J.S. Skotnicki, S. Tam, and K.M. Cunningham, Synthesis and SAR of highly selective MMP-13 inhibitors, Bioorg. Med. Chem. Lett. 15 (2005), pp. 4961–4966. doi:https://doi.org/10.1016/j.bmcl.2005.08.001.
- S. Sanyal, S.A. Amin, N. Adhikari, and T. Jha, QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors, SAR QSAR Environ. Res. 30 (2019), pp. 247–263. doi:https://doi.org/10.1080/1062936X.2019.1588159.
- Discovery Studio 3.0, Accelrys Inc., San Diego, USA, 2011. Available at http://www.accelrys.com.
- C.W. Yap, PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474. doi:https://doi.org/10.1002/jcc.21707.
- S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors, J. Mol. Struct. 1143 (2017), pp. 49–64. doi:https://doi.org/10.1016/j.molstruc.2017.04.020.
- QSAR tools, DTC laboratory, India, 2021; Software available at https://dtclab.webs.com/software-tools.
- Statistica 7.1, StatSoft Inc., 2300 East 14th Street Tulsa, OK 74104, United States of America.
- A. Nandy, S. Kar, and K. Roy, Linear discriminant analysis for skin sensitisation potential of diverse organic chemicals, Mol. Simul. 39 (2013), pp. 432–441. doi:https://doi.org/10.1080/08927022.2012.738421.
- M. Gálvez-Llompart, M.C. Recio, and R. García-Domenech, Topological virtual screening: A way to find new compounds active in ulcerative colitis by inhibiting NF-κ B, Mol. Divers. 15 (2011), pp. 917–926. doi:https://doi.org/10.1007/s11030-011-9323-4.
- N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches, Struct. Chem. 29 (2018), pp. 285–297. accessed on 25 Feb 2021. Available at http://sarpy.sourceforge.net/
- W. Tang, J. Chen, and H. Hong, Development of classification models for predicting inhibition of mitochondrial fusion and fission using machine learning methods, Chemosphere 273 (2021), pp. 128567. doi:https://doi.org/10.1016/j.chemosphere.2020.128567.
- G. Gini, T. Ferrari, A. Lombardo, A. Cassano, and E. Benfenati, A new QSAR model for acute fish toxicity based on mined structural alerts, J. Toxicol. Risk Assess. 5 (2019), pp. 016. doi:https://doi.org/10.23937/2572-4061.1510016.
- C. Campestre, M. Agamennone, P. Tortorella, S. Preziuso, A. Biasone, E. Gavuzzo, G. Pochetti, F. Mazza, O. Hiller, H. Tschesche, and V. Consalvi, N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: Mode of binding in a complex with MMP-8, Bioorg. Med. Chem. Lett. 16 (2006), pp. 20–24. doi:https://doi.org/10.1016/j.bmcl.2005.09.057.
- G. Pochetti, E. Gavuzzo, C. Campestre, M. Agamennone, P. Tortorella, V. Consalvi, C. Gallina, O. Hiller, H. Tschesche, P.A. Tucker, and F. Mazza, Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates, J. Med. Chem. 49 (2006), pp. 923–931. doi:https://doi.org/10.1021/jm050787+.